-
2023-509810-13-00
4
2023-05-13
Acute Lymphoblastic Leukemia (ALL)
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2022-500479-29-00
10
2023-03-28
International Prognostic Scoring System-Revised (IPSS-R) Low - or Inte
-
2022-500257-16-00
5
2023-03-17
Diabetic Foot Infections
-
2023-505277-32-00
5
2023-01-26
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2023-507031-38-00
5
2023-01-09
Severe viral lung infections
-
2023-504226-18-00
5
2022-11-30
NMDAR or LGI1 mediated autoimmune Encephalitis
-
2023-506548-18-00
10
2022-11-10
Dermatitis atopic
-
2022-500461-28-06
5
2022-09-15
High-Risk Metastatic Hormone-Sensitive Prostate Cancer
-
2024-516066-11-00
5
2022-08-31
Patients with newly diagnosed, histologically confirmed, primary advan
-
2022-503012-16-00
5
2022-07-20
Patients on treatment with Factor Xa Inhibitor needing for an urgent i
-
2023-509715-91-00
5
2022-05-06
Fabry’s disease
-
2023-509138-21-00
5
2021-08-26
Pulmonary Arterial Hypertension (PAH)
-
2024-511267-28-00
5
2021-02-17
B-cell malignancies
-
2023-506784-33-00
5
2021-01-19
RET fusion-Positive NSCLC
-
2023-503465-33-00
5
2020-07-03
Cholestasis
-
2024-512657-24-00
10
2014-03-27
Acute Lymphoblastic Leukaemia
-
2024-516993-31-00
5
2026-05-11
Renal Cell Carcinoma
-
2025-523975-48-00
5
2026-05-08
Obesity
-
2023-509628-16-00
5
2026-05-07
Small Cell Lung Cancer (SCLC)
-
2025-523123-22-00
5
2026-05-07
Chronic Kidney Disease
-
2025-523938-10-00
5
2026-05-05
Diabetic Macular Edema (DME)
-
2025-523974-18-00
5
2026-04-30
Obesity
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity